E-LIB Suche - Ergebnisse für: D'Erasmo L

1

Lomitapide hepatic safety: A long-term retrospective analys..:

Cegla, J. ; Larrey, D. ; D'Erasmo, L...
Atherosclerosis Plus. 54 (2023) - p. S2-S3 , 2023

2

OC 10.4 Proprotein Convertase Subtilisin Kexin Type 9 Inhib..:

Cammisotto, V. ; Baratta, F. ; Nocella, C....
Research and Practice in Thrombosis and Haemostasis. 7 (2023) - p. 100582 , 2023

Link: https://doi.org/10.1016/..

3

Lomitapide effectively reduces triglyceride (TG) levels in ..:

Cefalù, A.B. ; D'Erasmo, L. ; Giammanco, A....
Atherosclerosis. 355 (2022) - p. 45 , 2022

Link: https://doi.org/10.1016/..

4

Lomitapide in the long-term real-world management of HoFH –..:

Cegla, J. ; d'Erasmo, L. ; Steward, K....
Atherosclerosis Plus. 49 (2022) - p. S2-S3 , 2022

Link: https://doi.org/10.1016/..

5

The genetic lack of ANGTPL3 does not alter HDL functionalit:

Minicocci, I. ; Ossoli, A. ; Turri, M....
Atherosclerosis. 355 (2022) - p. 16-17 , 2022

Link: https://doi.org/10.1016/..

6

Real-world use of PCSK9 inhibitors in familial hypercholest..:

D'Erasmo, L. ; Arca, M. ; Celant, S....
Atherosclerosis. 355 (2022) - p. 11 , 2022

Link: https://doi.org/10.1016/..

7

Lomitapide in the long-term real-world management of HoFH –..:

D'Erasmo, L. ; Steward, K. ; Di Costanzo, A....
Atherosclerosis. 355 (2022) - p. 28 , 2022

Link: https://doi.org/10.1016/..

8

Role of NAFLD-associated genetic variants on renal function..:

Di Costanzo, A. ; Baratta, F. ; D'Erasmo, L....
Atherosclerosis. 355 (2022) - p. 198-199 , 2022

Link: https://doi.org/10.1016/..

9

ANGPTL3 and PCSK9 interact and show coordinated metabolic r..:

Bini, S. ; Pecce, V. ; D'Erasmo, L....
Atherosclerosis. 355 (2022) - p. 86 , 2022

Link: https://doi.org/10.1016/..

10

ANGPTL3 deficiency associates with expanded regulatory T ce..:

D'Erasmo, L. ; Minicocci, I. ; Di Costanzo, A....
Atherosclerosis. 331 (2021) - p. e12 , 2021

Link: https://doi.org/10.1016/..

11

High TG to HDL ratio plays a significant role on atheroscle..:

Scicali ; D'Erasmo, L. ; Cluzel, P....
Atherosclerosis. 331 (2021) - p. e237 , 2021

Link: https://doi.org/10.1016/..

12

Application of ACMG guidelines for classification of varian..:

Minicocci, I. ; Di Costanzo, A. ; D'Erasmo, L....
Atherosclerosis. 331 (2021) - p. e217 , 2021

Link: https://doi.org/10.1016/..

13

Evaluation of the real-world efficacy effectiveness and saf..:

Steward, K. ; Van Lennep, J. E. Roeters ; Arca, M....
Atherosclerosis. 331 (2021) - p. e54 , 2021

Link: https://doi.org/10.1016/..

14

Monogenic versus polygenic familial hypercholesterolemia: g..:

Minicocci, I. ; D'Erasmo, L. ; Di Costanzo, A....
Atherosclerosis. 315 (2020) - p. e25-e26 , 2020

Link: https://doi.org/10.1016/..

15

Impaired HDL cholesterol efflux capacity in subjects with m..:

Di Costanzo, A. ; Ronca, A. ; D'Erasmo, L....
Atherosclerosis. 315 (2020) - p. e155 , 2020

Link: https://doi.org/10.1016/..